Delivery Order SPE2DB22D2009-SPE2DB25FM1RF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 22, 2025, with a ceiling value of $2,176.72 and an ultimate completion date of September 23, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive procurement process. The point of performance is located at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 mL pen injections with a ceiling value of $1,088.36. This contract, issued on May 23, 2025, represents a firm fixed price delivery order with an ultimate completion date of May 27, 2025 and carries no set-aside designation. The award was made through competitive procurement processes and serves as a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $6,235.50. This competitively awarded, firm fixed-price delivery order was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $1,904.63 to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 15 mg/0.5 ml pens on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a GLP-1 receptor agonist used for diabetes management, representing part of...
- The Defense Logistics Agency awarded a $3,537.17 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 mL pens in 0.5 mL unit doses. The contract, which is a non-set-aside competitive award with an ultimate completion date of July 25, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 15, 2025. This firm fixed-price, non-set-aside delivery order, which is due for completion by September 16, 2025, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $1,632.54 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 mL pens with a completion date of July 22, 2025. This firm fixed price delivery order is unclassified with no set-aside provisions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a GLP-1 receptor agonist indicated for diabetes management, representing part of the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 10 mg/0.5 mL pens on August 20, 2025, with a ceiling value of $1,075.33 and an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order was placed without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a widely used diabetes...
- The Defense Logistics Agency awarded a $1,197.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pens on August 25, 2025, with an ultimate completion date of August 26, 2025. This non-set-aside competitive award represents a pharmaceutical supply delivery executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through...
- The Defense Logistics Agency awarded a delivery order valued at $33,315.11 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL units). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and was competitively awarded without set-aside designations. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM1RFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 7.5 mg/0.5 mL pens in a quantity of 0.5 mL units on September 24, 2025. This firm fixed-price delivery order carries a ceiling value of $1,713.04 and is scheduled for completion by September 25, 2025. The award is unclassified as a set-aside contract and represents a competitively awarded transaction. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Mounjaro is a GLP-1 receptor agonist used for diabetes management, consistent with AmerisourceBergen's extensive portfolio of specialty medications supplied to federal healthcare customers, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/24/25 |